Related Experiment Video
Updated: May 14, 2026
05:25
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Castelli Risk Index and its association with benign prostatic hyperplasia: data from a nationwide Chinese cohort
Hongpeng Fang1, Suqing Zhao2, Haodong Li1
1Department of Urology. General Hospital of Southern Theater Command.
Nutricion Hospitalaria
|May 13, 2026
Summary
Higher Castelli Risk Indices (CRI-I and CRI-II) are linked to increased benign prostatic hyperplasia (BPH) risk in older Chinese men. Dyslipidemia may play a role in BPH development.
Area of Science:
- Cardiovascular Epidemiology
- Urology
- Metabolic Syndrome
Background:
- Benign prostatic hyperplasia (BPH) prevalence increases with age.
- Dyslipidemia is increasingly implicated in BPH pathogenesis.
- The specific association between Castelli Risk Indices (CRI-I and CRI-II) and BPH requires further investigation.
Purpose of the Study:
- To investigate the relationship between Castelli Risk Indices (CRI-I and CRI-II) and the risk of benign prostatic hyperplasia (BPH).
- To assess dose-response relationships and predictive ability in a Chinese cohort.
Main Methods:
- Cross-sectional study of 4,974 Chinese men from the China Health and Retirement Longitudinal Study (2015).
- Multivariable logistic regression and restricted cubic spline models were employed.
- Adjusted analyses included subgroup and ROC curve evaluations.
Main Results:
- A 1-unit increase in CRI-I and CRI-II correlated with a 10.9% and 17.4% higher BPH risk, respectively.
- Significant linear dose-response relationships were observed.
- Associations were consistent across subgroups, particularly in older men, smokers, and alcohol consumers.
Conclusions:
- Elevated CRI-I and CRI-II are independent risk factors for BPH.
- These indices may serve as accessible biomarkers for BPH risk stratification.
- The findings underscore the role of dyslipidemia in BPH pathogenesis.
